CYTK – cytokinetics, incorporated (US:NASDAQ)
Stock Stats
News
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]
Form 4 CYTOKINETICS INC For: Nov 18 Filed by: Blum Robert I
Form 8-K CYTOKINETICS INC For: Nov 18
Form 144 CYTOKINETICS INC Filed by: Blum Robert I
Form SC 13G CYTOKINETICS INC Filed by: T. Rowe Price Investment Management, Inc.
Form 4 CYTOKINETICS INC For: Nov 12 Filed by: Malik Fady Ibraham
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.